Complete guide to sermorelin (GHRH 1-29), the growth hormone releasing hormone analog. Learn how it works, research findings, comparison to other GH peptides, and what science shows.

Sermorelin: Complete GHRH Analog Guide

Research Disclaimer

This article is for educational and research purposes only. The information provided does not constitute medical advice. Consult qualified healthcare professionals before making any health-related decisions.

Quick Facts

Property	Value
Full Name	Growth Hormone Releasing Hormone (1-29)
Type	GHRH analog
Amino Acids	29
Molecular Weight	3357.88 g/mol
CAS Number	86168-78-7
Former Brand Name	Geref (discontinued)
FDA History	Previously approved for pediatric GH deficiency

What is Sermorelin
How Sermorelin Works
Research Findings
Sermorelin vs Other GH Peptides
Potential Benefits
Side Effects
Dosing in Research
Frequently Asked Questions
References

What is Sermorelin

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). The full GHRH molecule has 44 amino acids, but research showed that only the first 29 are needed for biological activity.

Key Points

Truncated GHRH: Contains amino acids 1-29 of native GHRH
Full biological activity: The C-terminal portion (30-44) is not needed for receptor binding
Clinical history: Was FDA-approved as Geref for pediatric GH deficiency
Mechanism: Stimulates pituitary to release growth hormone naturally

Why 1-29?

Native GHRH (1-44):
[1-29: Active portion][30-44: Not required]
        ↓
Sermorelin (1-29):
[1-29: Full activity retained]

The first 29 amino acids contain everything needed for GHRH receptor binding and activation.

How Sermorelin Works

The GH Axis

Hypothalamus
    ↓ (releases GHRH)
Pituitary Gland
    ↓ (releases GH)
Liver + Tissues
    ↓ (produces IGF-1)
Effects throughout body

Sermorelin mimics the hypothalamus signal, telling the pituitary to release growth hormone.

Mechanism of Action

Step	Process
1	Sermorelin binds GHRH receptors on pituitary somatotrophs
2	Activates cAMP signaling pathway
3	Enhances GH gene transcription
4	Stimulates GH synthesis and release
5	GH enters circulation in pulsatile pattern

Why This Matters

Unlike direct GH injection:

Physiological release: GH is released in natural pulses
Feedback preserved: Body's regulatory systems remain intact
Pituitary function: May help maintain pituitary health
Lower risk: Less likely to cause GH excess

Research Findings

Clinical History

Sermorelin has one of the strongest research backgrounds of any peptide:

Study Type	Status
Phase I trials	Completed
Phase II trials	Completed
Phase III trials	Completed
FDA approval	Granted (1997), later discontinued
Post-market studies	Multiple

Key Research Areas

Pediatric GH Deficiency:

FDA-approved indication
Effective at stimulating GH in deficient children
Maintained pituitary function

Adult GH Decline:

Studies in adults with age-related GH decline
Increased IGF-1 levels documented
Improved body composition in some studies

Sleep and GH Release:

GHRH administration enhances slow-wave sleep
GH is primarily released during deep sleep
Potential synergy between sleep quality and GH

Research Limitations

Limitation	Impact
Most data from deficient populations	May not apply to normal GH levels
Discontinued product	Less recent clinical data
Variable individual response	Not everyone responds equally
Long-term data limited	Chronic use effects unclear

Sermorelin vs Other GH Peptides

GHRH Analogs

Peptide	Type	Half-Life	Notes
Sermorelin	GHRH (1-29)	10-20 min	Original, well-studied
CJC-1295 (no DAC)	Modified GHRH	30 min	More stable
CJC-1295 DAC	Modified GHRH	Days	Extended release
Tesamorelin	GHRH analog	30 min	FDA-approved for lipodystrophy

GHRH vs GHRP

Feature	GHRH (Sermorelin)	GHRP (Ipamorelin, GHRP-6)
Mechanism	GHRH receptor	Ghrelin receptor
Action	Stimulates GH synthesis + release	Amplifies GH release
Hunger effect	Minimal	Variable (GHRP-6 high, Ipamorelin low)
Cortisol effect	Minimal	Variable by peptide
Synergy	Works with GHRPs	Works with GHRHs

Why Combine Them?

GHRH alone: Moderate GH release
GHRP alone: Moderate GH release
GHRH + GHRP: Synergistic (greater than additive)

Research shows combining GHRH and GHRP peptides produces significantly more GH release than either alone.

Potential Benefits

What Research Suggests

Area	Evidence Level	Notes
GH stimulation	Strong	Well-documented in clinical trials
IGF-1 increase	Strong	Consistent finding
Body composition	Moderate	Some studies show improvements
Sleep quality	Moderate	GHRH linked to slow-wave sleep
Skin/hair	Limited	Anecdotal, indirect via GH
Recovery	Limited	Theoretical via GH effects

Important Context

These are research observations, not guaranteed outcomes:

Individual response varies significantly
Effects depend on baseline GH status
Age affects response (younger typically respond better)
Timing and dosing matter

Side Effects

Common (from clinical data)

Side Effect	Frequency	Notes
Injection site reactions	Common	Redness, swelling at site
Facial flushing	Occasional	Usually temporary
Headache	Occasional	Typically mild
Dizziness	Rare	Usually transient
Nausea	Rare

Theoretical Concerns

Concern	Explanation
Tumor growth	GH/IGF-1 could theoretically promote existing tumors
Joint pain	High GH levels can cause joint issues
Carpal tunnel	Associated with GH excess
Insulin resistance	Potential with elevated GH

Who Should Avoid

History of cancer (especially hormone-sensitive)
Active malignancy
Pituitary tumors
Diabetic retinopathy
Hypersensitivity to GHRH

Dosing in Research

Clinical Trial Dosing

From published research:

Population	Typical Dose	Frequency
Pediatric (approved)	0.03 mg/kg/day	Once daily at bedtime
Adult studies	100-300 mcg	1-2x daily
Research protocols	Variable	Often bedtime dosing

Research Considerations

Timing:

Bedtime dosing aligns with natural GH release
Fasted state may enhance response
Avoid post-meal administration

Duration:

Effects typically seen within weeks
Long-term protocols varied in studies
Cycling approaches used in research

Important Notes

These are research reference points, not recommendations
Individual dosing requires medical supervision
Response varies significantly between individuals

Sermorelin: Lower risk of GH excess (body regulates final output)
HGH: More direct control but bypasses feedback mechanisms

Neither is "safe" or "unsafe" absolutely—context matters.

Summary

Sermorelin is one of the most well-researched GH-releasing peptides:

Aspect	Status
Clinical history	Extensive (former FDA approval)
Mechanism	Well-understood (GHRH receptor)
Safety data	More available than most peptides
Effectiveness	Documented for GH stimulation
Current status	Research compound

Key Takeaways

Proven GH stimulation - Clinical trials document effectiveness
Physiological approach - Stimulates natural GH release vs direct injection
Synergy potential - Combines well with GHRP peptides
Good safety profile - Relative to clinical history
Research compound - Not currently FDA-approved for any indication

References

Thorner MO, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents. Horm Res. 1996;45(1-2):100-105.
Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
Corpas E, et al. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39.
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-314.
Merriam GR, et al. Growth hormone-releasing hormone treatment in normal aging. J Anti-Aging Med. 2001;4(4):331-343.
Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion. J Clin Endocrinol Metab. 1998;83(2):362-369.
Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.
Iranmanesh A, et al. Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. J Clin Endocrinol Metab. 1990;70(1):155-161.

Last updated: May 8, 2026

Reviewed by: Scientific Aminos Editorial Board